Sugammadex-Associated Hypotension, Bradycardia, Asystole, and Death

Kazim Mirza, Kathryn Landoski, Dilip Thakar, Jagtar Heir-Singh, Timothy Jackson, Cynthia Kassab

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


On December 16, 2015, the Food and Drug Administration (FDA) in the United States approved sugammadex (Bridion, Merck and Co), a modified gamma-cyclodextrin, to be used as a reversal agent. It is a first and unique selective nondepolarizing steroidal muscle relaxant (NDSMR) binding agent with a great affinity for rocuronium and vecuronium. However, there have been several recently published case reports of bradycardia and asystole immediately after sugammadex administration for the reversal. This report presents a case of sugammadex administration followed by rapidly progressing bradycardia leading to asystole and subsequent death. The family has provided the written consent to share this case report.

Original languageEnglish (US)
Pages (from-to)8767195
JournalCase Reports in Anesthesiology
StatePublished - 2020


Dive into the research topics of 'Sugammadex-Associated Hypotension, Bradycardia, Asystole, and Death'. Together they form a unique fingerprint.

Cite this